Understanding the Market | VISEN PHARMA-B rose over 4% as Parathyroid Hormone completed its first prescription in Boao recently
I'm PortAI, I can summarize articles.
VISEN PHARMA-B's stock price rose by more than 4%, with an increase of 4.68% as of the time of publication, reported at HKD 39.8. Recently, the first prescription of Parathyroid Hormone was completed in Boao. This drug has been approved in Europe and the United States and is the world's first parathyroid hormone replacement therapy. The company's CEO stated that this move is an important step in innovation in the endocrine field and will accelerate the process of obtaining domestic approval for the drug and promote product commercialization in collaboration with partners
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments